Stifel Nicolaus Lowers Beta Bionics (NASDAQ:BBNX) Price Target to $25.00

Beta Bionics (NASDAQ:BBNX) had its price target cut by investment analysts at Stifel Nicolaus from $31.00 to $25.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 72.89% from the stock’s previous close.

A number of other research firms have also recently weighed in on BBNX. The Goldman Sachs Group restated a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Thursday, January 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. TD Cowen began coverage on shares of Beta Bionics in a report on Monday, January 26th. They set a “hold” rating and a $17.00 target price for the company. Lake Street Capital upped their price target on shares of Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Finally, Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.64.

Beta Bionics Stock Up 5.5%

Shares of NASDAQ BBNX opened at $14.46 on Wednesday. The business’s 50 day moving average price is $25.28 and its two-hundred day moving average price is $22.69. The company has a market cap of $636.67 million and a PE ratio of -3.31. Beta Bionics has a twelve month low of $8.89 and a twelve month high of $32.71.

Insider Buying and Selling

In other news, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the transaction, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mike Mensinger sold 7,800 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.61, for a total value of $230,958.00. Following the completion of the sale, the insider owned 82,952 shares of the company’s stock, valued at approximately $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 32,490 shares of company stock worth $960,835.

Institutional Trading of Beta Bionics

Several large investors have recently modified their holdings of BBNX. GPS Wealth Strategies Group LLC increased its position in shares of Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares during the period. Strs Ohio acquired a new position in shares of Beta Bionics in the 1st quarter valued at approximately $29,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Beta Bionics by 139.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after acquiring an additional 1,863 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after acquiring an additional 2,639 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.